Dosing Guidelines for Cabozantinib in Combination with PD-1

The combination of Cabozantinib and PD-1 inhibitors has shown significant results in cancer treatment. This combination therapy can enhance anti-tumor immunity and improve treatment effects. However, correct dosing is crucial to ensure the safety and effectiveness of the treatment.

For medullary thyroid cancer, the recommended dose of cabozantinib is 140 mg once daily. The recommended starting dose for patients with mild and moderate hepatic impairment is 80 mg. The recommended dose of cabozantinib for the treatment of kidney, liver, and lung cancer is 60 mg once daily.

For the control of bone metastasis, the recommended dose is 40 mg once a day. When cabozantinib is used in combination with a PD-1 inhibitor, the dose can be 40 mg or 60 mg once a day. The specific dose should be determined based on the patient's specific condition and the guidance of the doctor.

PD-1The dosage of an inhibitor will vary based on the specific drug and the individual patient's condition. Typically, doses of these drugs are administered based on body surface area or as fixed doses. When used in combination with cabozantinib, the respective drug package inserts and physician recommendations should be consulted to determine the optimal dose.

Before starting combination therapy, a comprehensive assessment of the patient's overall health status, including liver and kidney function, heart function, etc. should be conducted. During coadministration, patient response, including therapeutic efficacy and possible side effects, should be closely monitored. If adverse reactions occur, the drug dosage should be adjusted or discontinued in time and communicated with the doctor. Combined medication may increase the risk of certain side effects, such as fatigue, diarrhea, rash, etc. Patients should be aware of and prepared.